

Olfactory system pathology in Alzheimer's Disease

Citation for published version (APA):

Son, G. (2021). *Olfactory system pathology in Alzheimer's Disease: evidences from rodent and human studies*. [Doctoral Thesis, Maastricht University]. Gildeprint Drukkerijen. <https://doi.org/10.26481/dis.20210526gs>

Document status and date:

Published: 01/01/2021

DOI:

[10.26481/dis.20210526gs](https://doi.org/10.26481/dis.20210526gs)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy


If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Appendix

Valorization



Given that Alzheimer's disease (AD) is progressive and incurable, the current principal application against AD progression is an early identification for appropriate clinical intervention. Although researchers in universities, pharmaceutical industries, and medical centers have endeavored to discover effective monitoring and diagnostic method of AD, it remains incomplete.

As an early symptom of AD, olfactory dysfunction has important implications. The olfactory system has generated a great deal of interest in recent years as a novel tool for diagnosis. In specific, an olfactory test for AD has been proposed for clinical research over the last 30 years. The findings in this thesis provide scientific evidence about partial hyposmia or specific anosmia in AD and imply the significance of development measuring AD-specific olfactory dysfunction. Notably, partial hyposmia is a significant discovery because it can develop diagnostic methods that can easily monitor a mild cognitive impairment group. Even it might be applied to cognitively asymptomatic groups in AD progression. Moreover, the mechanism between the olfactory dysfunction in AD progression and the misfolded protein (e.g., amyloid-beta) accumulated in the olfactory system can lead to a new concept in AD therapeutic strategies.

Furthermore, olfactory pathology allows us to speculate that the impaired olfactory epithelium includes altered cellular and molecular components. In this regard, nasal discharge from the olfactory epithelium may feasibly contain high-throughput biological material information that mirrors AD pathological changes in the olfactory system that could be linked to the olfactory epithelium. The results of

this thesis indicated a positive correlation between the biomarkers' level in nasal discharge and AD progression. Nasal discharge biomarker would be a better option to screen for AD because of the advantages; AD-specific early detection, economic accessibility, and non-invasive sample collection. This new diagnostic resource will aid much convenient and more accessible detection of AD before the laborious and expensive diagnosis in the clinic, thus bringing much relief to millions suffering from AD.

Correspondingly, these findings about olfactory neuropathology may provide a new platform for conducting preclinical and clinical studies to improve diagnostics in AD and better understand the mechanisms behind neurodegeneration in AD.

